07.06.18
MGMT promoter methylation associated with improved survival for patients with WHO Grade II Gliomas
![](https://healthproblemsnews.com/wp-content/uploads/sites/5/2018/04/ZtJtRQiQIspviGDStRJA-150x150.jpg)
Further exploration into the endpoints of the NRG Oncology/RTOG 0424 trial resulted in the discovery that MGMT promoter methylation is an independent prognostic biomarker of high-risk, low-grade glioma treated with temozolomide and radiation. This is the first study of its kind to validate the prognostic significance of MGMT promoter methylation in this patient population and